Al-Ncd
Schizophreniform Disorder
University of California, Los AngelesPhase 4 / ApprovedDormant
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 95/ 100
Competitive context
5 Active assets in the Schizophreniform Disorder cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Raloxifene Iris Sommer | Phase 4 | A |
Olanzapine Alkermes, Inc. | Phase 4 | A |
Bxcl501 BioXcel Therapeutics Inc | Phase 4 | A |
N-Acetyl-L-Cysteine University of Maryland, Baltimore | Phase 4 | BBB |
Risperdal Northwell Health | Phase 4 | BBB |
View all 41 →
Same molecule, other indications
Al-Ncd is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →